300
Participants
Start Date
March 1, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2027
In-Person Outcome Assessment
Assessments will be administered to evaluate participant outcome status
3T Magnetic Resonance Imaging (MRI)
Participants will be asked to complete a 3T MRI
Clinical Visit
Patients who screen positive for PTE will have an in-depth clinical visit
Blood Draw
Blood Draw for Plasma, DNA, Serum, RNA
EEG
An EEG will be performed on patients who screen positive for PTE at the clinical visit
Telephone Outcome Assessment
Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
University of Pittsburgh, Pittsburgh
University of Pennsylvania/Penn Presbyterian Medical Center, Philadelphia
University of Cincinnati, Cincinnati
University of Texas Southwestern, Dallas
Baylor College of Medicine, Houston
University of Texas at Austin, Austin
University of California, San Francisco, San Francisco
University of Washington, Seattle
Spaulding Rehabilitation Hospital, Charlestown
United States Department of Defense
FED
University of Pennsylvania
OTHER